CLDN18.2 in colorectal mucinous adenocarcinoma: a lineage-associated biomarker and emerging translational target.

Yu W, Wei S, Wan S, Chen Y, Huang Q

Open source

DOI
10.3389/fphar.2026.2001935
Published
2026
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.2001935,
  title = {CLDN18.2 in colorectal mucinous adenocarcinoma: a lineage-associated biomarker and emerging translational target.},
  author = {Yu W and Wei S and Wan S and Chen Y and Huang Q},
  year = {2026},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2026.2001935},
  url = {https://doi.org/10.3389/fphar.2026.2001935}
}

RIS

TY  - JOUR
TI  - CLDN18.2 in colorectal mucinous adenocarcinoma: a lineage-associated biomarker and emerging translational target.
AU  - Yu W
AU  - Wei S
AU  - Wan S
AU  - Chen Y
AU  - Huang Q
PY  - 2026
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.2001935
UR  - https://doi.org/10.3389/fphar.2026.2001935
ER  - 

APA

W, Y., S, W., S, W., Y, C., & Q, H. (2026). CLDN18.2 in colorectal mucinous adenocarcinoma: a lineage-associated biomarker and emerging translational target.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.2001935

Source records